Keywords: Bristol-Myers Squibb, NeurOp, Major depresssion, License, CNS
Bristol-Myers Squibb buys rights to depression drug compounds from NeurOp for a potential $75.5 million
Article | 31 March 2010
Atlanta, USA-based preclinical stage drug developer NeurOp Chas entered into a collaboration with drug major Bristol-Myers Squibb focused upon the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
